Version May 2024
Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician if symptoms occur. As with all allergenic extracts, severe systemic reactions may occur, and in certain individuals these reactions may cause death. Patients should be observed for at least 20 minutes after skin tests have been completed. Emergency measures as well as personnel trained in their use should be immediately available in the event of a life threatening reaction.
This product is intended for use by physicians who are experienced in the administration of allergenic extracts or for use under the guidance of an allergy specialist. Skin tests should be performed after the patient's physical well being and allergic history have been evaluated.
This product should never be injected intravenously.
Diagnostic aid: Intradermal: 0.1 mL to create a distinct bleb approximately 5 mm in diameter, examine reaction site in 15 to 20 minutes; induration may also appear in 24 to 48 hours; sites showing a wheal or flare response should be scored based on mm reference scale.
Refer to adult dosing.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
Cardiovascular: Bradycardia, hypotension, syncope
Dermatologic: Pallor, urticaria
Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity exacerbation
Ophthalmic: Conjunctivitis
Respiratory: Cough, rhinitis, wheezing
Extreme sensitivity to an allergen; recent myocardial infarction (MI); poorly controlled asthma; concurrent beta-adrenergic blocker treatment; acute exacerbation of allergies or asthma; acute infection or flu accompanied by fever; excessive exposure to clinically relevant allergen prior to skin testing
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Concerns related to adverse effects:
• Allergic reactions: [US Boxed Warning]: Severe reactions may occur (may be fatal); monitor for 20 minutes after testing; medications for the treatment of reactions should be available for immediate use. Excessive local and systemic reactions are more possible during skin testing in patients with recent contact with the allergen.
Concurrent drug therapy:
• Antihistamines/sympathomimetics: The use of antihistamines or sympathomimetics should be avoided for ≥24 hours prior to skin testing; reactivity of the skin may be affected by these agents.
Other warnings/precautions:
• Experienced physician: [US Boxed Warning]: Should be administered under the supervision of a physician experienced in administration of allergenic extracts.
• Not for intravenous administration: [US Boxed Warning]: For intradermal administration only; do not administer intravenously.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Subcutaneous:
Generic: 1:20 (5 mL, 10 mL, 50 mL)
Yes
Solution (Trichophyton Mentag (Diagnost) Subcutaneous)
1:20 (per mL): $21.84
Solution (Trichophyton Mentagrophytes Subcutaneous)
1:20 (per mL): $32.04
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Clean skin with alcohol prior to administering (allow to dry completely). Administer by intradermal injection into volar surface of forearm and four rows on the back; do not administer IV Patients should be observed for 20 minutes following test and instructed to return to office or ED if signs or symptoms of allergic reaction occur.
Intradermal: Clean skin with alcohol prior to administering (allow to dry completely). Administer by intradermal injection into volar surface of forearm and four rows on the back; do not administer IV. Patients should be observed for 20 minutes following test and instructed to return to office or ED if signs or symptoms of allergic reaction occur.
Skin test in diagnosis of Type I hypersensitivity to Trichophyton fungus
None known.
There are no known significant interactions.
Animal reproduction studies have not been conducted. In normal pregnancies, cautious use is not expected to be harmful; however, due to the potential for histamine release to cause smooth muscle contraction, extensive testing should be avoided in pregnancy. Immunosuppressive changes during pregnancy may blunt the effects of skin testing. Avoid use in pregnancy unless clearly needed.
It is not known if Trichophyton skin test is excreted in breast milk. The manufacturer recommends that caution be exercised when administering Trichophyton skin test to nursing women.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
